Mainz Biomed Announces Pricing of Follow-on Offering
January 25 2022 - 8:00PM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, announced today the pricing of its
underwritten public follow-on offering (the “Follow-on Offering”)
of 1,500,000 ordinary shares at a public offering price of US$15.00
per ordinary share (the “Offering Price”), for gross proceeds of
$22,500,000.
The Follow-on Offering is being made pursuant to a registration
statement on Form F-1 filed with the U.S. Securities and Exchange
Commission (“SEC”). The Follow-on Offering is expected to close on
January 28, 2022, subject to the satisfaction of customary closing
conditions. In connection with the Follow-on Offering, Mainz Biomed
has granted the underwriter the option to purchase up to 225,000
additional ordinary shares at the Offering Price to cover
over-allotments, if any. All shares are being offered by Mainz
Biomed.
Boustead Securities, LLC is acting as the sole underwriter for
the offering. Ortoli Rosenstadt LLP served as counsel to Mainz
Biomed. Sichenzia, Ross and Ference LLP served as counsel to the
underwriter.
The offering is being made only by means of a prospectus. A copy
of the final prospectus related to the offering may be obtained,
when available, from Boustead Securities, LLC, via email:
offerings@boustead1828.com or by calling +1 (949) 502-4408 or
standard mail at Boustead Securities, LLC, Attn: Equity Capital
Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition,
a copy of the final prospectus, when available, relating to the
offering may be obtained via the SEC’s website at www.sec.gov.
About Mainz Biomed N.V.Mainz Biomed develops
market-ready molecular genetic diagnostic solutions for
life-threatening conditions. The Company’s flagship product is
ColoAlert, an accurate, non-invasive, and easy-to-use early
detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed in Europe with an FDA clinical study and
submission process intended to be launched in the first half of
2022 for U.S. regulatory approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information, please
visit www.mainzbiomed.com
For media enquiries, please
contact press@mainzbiomed.com
For investor enquiries, please
contact ir@mainzbiomed.com
Forward-Looking StatementsCertain statements
made in this press release are “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as
“anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”,
and “project” and other similar expressions that predict or
indicate future events or trends or that are not statements of
historical matters. These forward-looking statements reflect the
current analysis of existing information and are subject to various
risks and uncertainties. As a result, caution must be exercised in
relying on forward-looking statements. Due to known and unknown
risks, actual results may differ materially from the Company’s
expectations or projections. The following factors, among others,
could cause actual results to differ materially from those
described in these forward-looking statements: (i) the failure to
meet projected development and related targets; (ii) changes in
applicable laws or regulations; (iii) the effect of the COVID-19
pandemic on the Company and its current or intended markets; and
(iv) other risks and uncertainties described herein, as well as
those risks and uncertainties discussed from time to time in other
reports and other public filings with the Securities and Exchange
Commission (the “SEC”) by the Company. Additional information
concerning these and other factors that may impact the Company’s
expectations and projections can be found in its filings with the
SEC, including its registration statement filed on January 21,
2022. The Company’s SEC filings are available publicly on the SEC’s
website at www.sec.gov. Any forward-looking statement made by us in
this press release is based only on information currently available
to Mainz Biomed and speaks only as of the date on which it is made.
Mainz Biomed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024